TECHNICAL NOTES

Juroclav

Broad Spectrum Antibiotic Tablets



Active Constituents

Each tablet of Juroclav 50, Juroclav 250 or Juroclav 500 contains both clavulanic acid (as clavulanate potassium) 10 mg, 50 mg or 100 mg; and amoxicillin (as amoxicillin trihydrate) 40 mg, 200 mg or 400 mg.

Actions

Resistance to many antibiotics is caused by β-lactamase enzymes which destroy the antibiotic before it can act on the bacteria. The clavulanate in Juroclav counteracts this defence mechanism by inactivating the β-lactamases, thus rendering the organisms sensitive to amoxicillin's rapid bactericidal effect at concentrations readily attainable in the body.

Microbiology

In vitro, Juroclav is active against a wide range of clinically important bacteria, including:-

- **Gram-positive bacteria:** *Staphylococcus* spp. (including β-lactamase producing strains), *Corynebacterium* spp. and *Streptococcus* spp.;
- **Gram-negative bacteria:** *Escherichia coli* (including β-lactamase producing strains), *Salmonella* spp. (including β-lactamase producing strains), *Bordetella bronchiseptica*, *Pasteurella* spp., *Proteus mirabilis* and other sensitive strains and *Klebsiella* spp.

Juroclav is not indicated for cases involving *Pseudomonas* spp.

Indications

Juroclav 50 and 250 tablets: Clinically, Juroclav has been shown to be effective in treating a wide range of diseases of cats and dogs, including skin disease (deep and superficial pyodermas), urinary tract infection, respiratory disease (involving upper and lower respiratory tract) and enteritis. They have a notably broad spectrum of bactericidal activity against bacteria commonly found in cats and dogs, and are indicated for the oral treatment of bacterial infections caused by susceptible organisms.

Juroclav 500 tablets: Have a notably broad spectrum of bactericidal activity against bacteria commonly found in calves and dogs and are indicated for the oral treatment of bacterial infections caused by susceptible organisms. These include enteritis and respiratory infections in calves and dogs and skin infections in dogs.

Contraindications

Do not administer to small herbivores (e.g. guinea pigs) or animals with a history of allergic reactions to penicillins. Juroclav is not indicated for cases involving *Pseudomonas* spp.

® Registered Trademark of Jurox Pty Limited

Withholding Periods

Meat (Calves): Do not use less than 4 days before slaughter for human consumption.

Trade Advice

This product does not have an Export Slaughter Interval (ESI) established. For advice on the ESI contact Jurox Pty Limited on 1800 023 312 before using this product.

Dosage and Administration

For oral administration only. Juroclav 50 and 250 Tablets may be accepted from the hand, or alternatively, the tablets may be crushed and added to a little food.

Calves: Dose rate is 6.25 mg/kg (1 x 500 mg tablet/80 kg) bodyweight twice daily. Use a higher dose rate of 12.5 mg/kg (1 x 500 mg tablet/40 kg) bodyweight for the initial dose and for severely affected calves. Treatment should be continued until 12 hours after all symptoms have subsided. For example, a 40 kg calf requires one Juroclav 500 tablet initially, followed by one-half of a Juroclav 500 tablet twice daily. In severe cases, one Juroclav 500 tablet twice daily should be given.
Cats, dogs: The standard dose rate is 12.5 mg/kg (1 x 50 mg tablet/4 kg, 1 x 250 mg tablet/20 kg, 1 x 500 mg tablet/40 kg) bodyweight twice daily. Tablets can be halved or quartered as necessary. For the majority of infections, including those of the skin, urinary tract and gastrointestinal tract, the above dosing regimen has been found to be effective. Refractory cases, however, particularly those of the respiratory tract, have shown improved cure rates by doubling the dose to 25 mg/kg bodyweight twice daily.

Duration of Therapy

Routine cases involving all indications: therapy should be continued for five to seven days, or for 48 hours after all symptoms have subsided.
Chronic or refractory cases: in cases where there is considerable tissue damage, a longer course of therapy may be required to allow sufficient time for damaged tissue to repair. The following durations are suggested as guidelines: chronic skin diseases 10 to 20 days; chronic cystitis 10 to 28 days; respiratory disease 8 to 10 days.

GHS Information

For GHS Information see Safety Data Sheet.

Presentation

Tablets, 50 mg: 100s; 250 mg: 250s; 500 mg: 100s.

Storage

Store below 25°C (air conditioning) in a dry place.

Poisons Schedule

S4.

Registration Numbers

APVMA Nos. 61669 (50 mg), 61670 (250 mg), 61671 (500 mg).

AU - Tech Note - Juroclav Tablets / Sep 2018 / APPROVED

® Registered Trademark of Jurox Pty Limited